In cooperation with KMD, Qlife has extended the contract with Divisionsforeningen.
Qlife commences trading on Nasdaq First North Growth Market
Qlife Holding AB announces that the trading in the company’s shares (short name: QLIFE) will commence today on the Nasdaq First North Growth Market in Stockholm. Qlife Holding AB (“Qlife”) belongs to the health care sector and is the 6[th] company to be admitted to trading on Nasdaq’s Nordic markets* in 2020.
Qlife (https://qlifeholding.com/sv/home) is a high-tech medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it the most. Its main product, The Egoo Home System, is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient’s doctor, clinic or hospital via smartphone and computer. Qlife is headquartered in Helsingborg, Sweden.
“Today is a big milestone for Qlife. Going public has been a journey that would not have been possible if not for the incredible, dedicated team behind Qlife,” said Thomas Warthoe, CEO of Qlife. “I am humbled by the level of interest from investors who can see the same potential in Qlife as we do, and for how they want to help us help others. I am looking forward to developing the company together with my team and create value for customers and investors. There is no doubt that the real journey has just begun.”
“We welcome Qlife to the Nasdaq First North Growth Market,” said Adam Kostyál, SVP and Head of European Listings, Nasdaq. “We continue to see an inflow of innovative health care companies leveraging the Nasdaq First North Growth Market as a platform for growth, and we look forward to supporting Qlife on its continued journey as a publicly listed company.”
Qlife Holding AB has appointed G&W Fondkommission as the Certified Adviser.
*Main markets and the Nasdaq First North Growth Market at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm
Qlife's focus on professional sports is centered around COVID-19 testing, which the company offers in collaboration with IT partner KMD.
Jakob has extensive experience from international sales and business development within MedTech and healthcare and brings an excellent record of results and achievements in complex and competitive
In April we closed a contract with the professional Danish football league for regular testing of all players and staff for COVID-19 and delivery of test results were initiated already in week 22.
"Henrik Ljung brings broad experience to Qlife from financial reporting, IR, business control, finance management and corporate governance, all with a focus on fast-growing companies in the ea
KMD and Qlife has entered an agreement with Badmint
Geelmuyden Kiese and KMD announced earlier today that they have entered a partnership to provide smart and efficient Covid-19 test solutions for the professional sports, culture, and entertainment
The first phase of developing the antibody test will be outsourced to an existing partner and is expected to take approximately three months.
Resolution on adoption of accounts and allocation of the company’s result